Daiichi Sankyo Remains Bullish On Prasugrel, Rivoglitazone Despite Safety Concerns – R&D Day
This article was originally published in PharmAsia News
Executive Summary
TOKYO - Daiichi Sankyo provided a status report to investors during a Feb. 21 research and development update in Tokyo. In particular, company officials responded to investor safety concerns related to two key pipeline drugs - anti-platelet drug prasugrel (CS-747) and rivoglitazone (CS-011), a PPAR agonist for type 2 diabetes
You may also be interested in...
Daiichi Sankyo Says Ranbaxy Purchase Deteriorated Its Balance Sheet
TOKYO - Daiichi Sankyo expects the strong yen could reduce third- and fourth-quarter sales by ¥9 billion, but that for fiscal year 2008, the decrease will be pared by greater than expected performance of its Luipold Pharmaceutical subsidiary
Daiichi Sankyo Says Ranbaxy Purchase Deteriorated Its Balance Sheet
TOKYO - Daiichi Sankyo expects the strong yen could reduce third- and fourth-quarter sales by ¥9 billion, but that for fiscal year 2008, the decrease will be pared by greater than expected performance of its Luipold Pharmaceutical subsidiary
Forest Ends Daiichi Azor Deal To Focus On Its Own Products
Forest Laboratories regained the equivalent of 500 sales reps by terminating a three-year co-promotion deal with Daiichi Sankyo for the fixed-dose antihypertensive Azor, the company announced May 12.